Patients taking teprotumumab (marketed under the drug name Tepezza) for thyroid eye disease will want to pay attention to a small study released by researchers at the Stanford University School of Medicine. The study was based on evaluation of 26 patients that had been treated with at least four doses of Tepezza to treat their condition. Research indicated that 17 of those 26, or 65 percent, reported ...
Study Shows Link Between Tepezza and Hearing Loss
Posted December 22, 2022 in Product News and Recalls